Congenital Cytomegalovirus Infection
15
1
1
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
20.0%
3 terminated out of 15 trials
75.0%
-11.5% vs benchmark
27%
4 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular Risk
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Asymptomatic Congenital CMV Treatment
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial